Commentary|Videos|April 29, 2025
Leveraging RWD to Improve Reporting in Oncology
Author(s)Andy Studna, Senior Editor
In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses a recent study he led on the validity of using real-world data for reporting mortality.
Advertisement
In a recent video interview with Applied Clinical Trials, C.K. Wang, MD, chief medical officer, COTA, discussed a recent study he led on leveraging real-world data (RWD) to improve oncology reporting. Additionally, Wang highlighted recent trends and challenges in the oncology research space involving the use of RWD as well as real-world evidence (RWE).
ACT: Could you give our audience an overview of the recent study you led on leveraging RWD to improve reporting in oncology?
Wang: To start, COTA is an oncology real-world data company, and our data is clinical and comes from the actual medical record systems for our provider partners, and over the past six years, we have built large, ready to use databases across both blood cancers and solid tumors. I will say that two foundational components to when one is looking to use any real-world data set is to understand, number one, whether or not it is actually accurate, whether that you know that the data that you see is actually accurate, but more importantly is to understand how complete that data is. As we all know, in clinical trials, especially in oncology, overall survival remains the gold standard by which any new therapy is actually being looked at. The completeness of the mortality data, whether it be in the clinical trials or in real-world data, remains extremely important. This is exactly what we set out to do in our study. We looked at, across all of our hematologic cancer databases, and we compare the accuracy and the completeness of our composite mortality variable against the national death index, which is the gold standard death database as we know it today.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Why Many Health Tech Startups Miss the Mark in Clinical Trials
September 3rd 2025
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
- Why Clinical Trial Innovations Take Years to Gain Adoption
August 29th 2025
- Addressing the Digital Divide in Decentralized Trials
August 28th 2025
- Why Decentralized Trials Face Slow Adoption Despite Strong Data
August 26th 2025
- How Research Sites Balance Funding Cuts and Efficiency Pressures
August 26th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Driving Transformation With a Connected Clinical Platform: 2025 Veeva R&D and Quality Summit Clinical Opening Keynote
2
AstraZeneca’s Baxdrostat Shows Promise in Phase III Trial for Hard-to-Control Hypertension
3
Promising Trial Data Leads to Breakthrough Designation for Eli Lilly’s Investigational KRAS G12C Inhibitor in Advanced, Metastatic Non-Small Cell Lung Cancer
4
Merck’s Oral PCSK9 Inhibitor Demonstrates Efficacy in Hypercholesterolemia
5